Cyclodextrin Market size would exceed USD 390 million valuation by 2027, Says to Global Market Insights Inc.
The growth of the cyclodextrin market is driven by burgeoning demand for remdesivir injections due to COVID-19, expanding cosmetics &
Tag: Covid-19
Role of HPBCD in development of Pfizer’s novel COVID-19 oral antiviral treatment candidate
Pfizer’s breakthrough drug candidate PF-07321332 used in combination with ritonavir was poven to successfully reduce the risk of hospitalization and
METHYL-CYCLODEXTRIN FOR USE IN TREATING ENVELOPED VIRUS INFECTIONS SUCH AS SARS-CoV-2
The patent application (1) with priority date of 09. March 2020 claims that methyl bCD preferably with DS 0.7 (Crysmeb)
Memorial Sloan Kettering Cancer Center: Potential treatment of COVID-19 using inhalable camostat/nafamostat formulated with HPBCD or SBECD
Memorial Sloan Kettering Cancer Center (MSKCC) has filed a patent application on an inhalational therapeutic composition of camostat solubilized by
Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Harvard scientists discover the prophylactic effect of SBECD solubilized amodiaquine against SARS-CoV2 infection
Amodiaquine is a commonly used medicament for the treatment of malarial infections. It is a 4-aminoquinoline compound similar to chloroquine
Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries since
Safety of inhaled HPBCD-formulated ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study
SARS-CoV-2 replication in cell cultures has been shown to be inhibited by ivermectin. However, ivermectin’s low aqueous solubility and bioavailability hinders
Intraoral/intranasal niclosamide/HPBCD formulation for treatment of COVID-19
A recently published patent of Union Therapeutics, Denmark (US11045434) (granted extremely rapidly by USPTO within 8 months from filing date)
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis
The aim of the study was evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19. 52